Adaptive Software Inc

48


Adaptive Software Inc
Adaptive Software Inc is listed in the Computer System Designers & Consultants category in Syracuse, New York. Displayed below are the social networks for Adaptive Software Inc which include a Facebook page, a Linkedin company page and a Twitter account. The activity and popularity of Adaptive Software Inc on these social networks gives it a ZapScore of 48.

Contact information for Adaptive Software Inc is:
3005 Milton Ave
Syracuse, NY 13209
(315) 468-6238
Do you own or manage this business? Click here to claim the Adaptive Software Inc listing and add social networks, logos, descriptions and more.

Adaptive Software Inc Contact Information:

Social Posts for Adaptive Software Inc


Cosmetics May Provide Analogue for Dysregulation of Drugs bit.ly/2nYbS9W

Cosmetics May Provide Analogue for Dysregulation of Drugs
I like beauty products – well, it may be more accurate to say that I am interested in beauty products, since most days I only wear a swipe of mascara and concealer to work. However, there are some drawbacks to being interested in beauty; unlike for pharmaceuticals, there are no promises that any pro...

Post-grant oppositions for Pharma patents (Part 2): What advantages do they hold over district court...
As of this writing, patents protecting a number of drugs, including several blockbusters (e.g., Humira, Rituxan, Avastin, Tecfidera, Copaxone, etc.), are under scrutiny in inter partes review (IPR), putting these drugs at risk of early generic entry. In Part 1 of this series, we reviewed the type of...

Post-grant oppositions for pharma patents (Part 1): A primer
Since its introduction in 2012, the U.S. post-grant opposition (PGO) process, especially the inter partes review, has created a lot of buzz in the pharma sector, with more than 200 petitions filed in FY2016 against patents across therapy areas (AIA Trial Statistics,


Prostate cancer: furthering the field for PD-1/PD-L1 pathway inhibitors? bit.ly/2nY77Nr

Prostate cancer: furthering the field for PD-1/PD-L1 pathway inhibitors?
The Immune checkpoint inhibitors drug class has raised the bar for cancer treatment across multiple tumor types including NSCLC, malignant melanoma, bladder cancer, and Hodgkin’s lymphoma, and the list is rapidly expanding. Since Yervoy’s initial approval in malignant melanoma in 2011, three PD-1/PD...


Evaluating the validity of clinical outcome assessments: avoiding jingle-jangle fallacies! bit.ly/2nnmgFk

Evaluating the validity of clinical outcome assessments: avoiding jingle-jangle fallacies!
When selecting a suitable clinical outcome assessment for an upcoming trial, such as a disease-specific patient-reported outcome (PRO) measure, it is important to assess the construct validity of each scale. One way of achieving this is through assessing the convergence of each scale with others hyp...


Stop by booth 307 for your chance to win a Kindle Fire and $500 for the charity of your choice #AMCP2017 https://t.co/s5Trpj9XCX


California. Illinois. Maryland. New York. Massachusetts.Vermont. Contraceptives. What's the common denominator? bit.ly/2mYuEdj